Lung cancer trials in Italy

In Italy 272 Also abroad 2747

272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Bari, Bergamo, Florence, Milan, Naples, Palermo, Peschiera del Garda, Ravenna, Rome, Siena
Age
18 years and over
People
1,000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
Phase 3Taking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Catanzaro, Milan, Naples, Padova, Ravenna, Rome, Verona
Age
18 years and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
Phase 1/2Taking people
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Where
Florence, Meldola, Milan, Rome
Age
18 years to 64 years
People
170 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00
Phase 3Taking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Bergamo, Florence, Milan, Novara, Perugia, Rome
Age
18 years and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Bergamo, Florence, Milan, Modena, Monza, Perugia, Peschiera del Garda, Rome, Turin
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 3Taking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Aviano, Bergamo, Bologna, Catania, Fano, Florence, Genoa, Meldola, Milan, Monza, Orbassano, Padova, Parma, Ravenna, Rome, Rozzano, Verona
Age
18 years and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Ancona, Bari, Milan, Padova, Ravenna, Rome
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Bari, Brescia, Candiolo, Catania, Florence, Meldola, Milan, Monza, Naples, Parma, Perugia, Pesaro, Pisa, Rome, Udine
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 3Taking people
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Where
Alexandria, Padova, Perugia, Rome, Siena, Verona
Age
18 years and over
People
290 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317 · EU 2023-508773-82-00
Phase 3Taking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Milan, Monza, Naples, Orbassano, Parma, Perugia, Pisa, Rome, Rozzano, Verona
Age
18 years and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
No phaseTaking people
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Where
Acquaviva Delle Fonti, Bergamo, Fano (PU), Genoa, Lecce, Mestre, Milan, Misterbianco (CT), Modena, Naples, Novara, Palermo, Ravenna, Rome, Sassari, Trento, Verona
Age
18 years and over
People
700 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07284121
Phase 2Taking people
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Where
Aviano, Cagliari, Florence, Milan, Padova
Age
18 years and over
People
105 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00
Phase 1/2Taking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Meldola, Milan, Orbassano, Rome
Age
18 years and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Aviano, Genoa, Livorno, Milan, Misterbianco (CT), Modena, Monza MI, Naples, Pesaro, Peschiera Del Garda (VR), Rome, Statte, Trento
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Aviano, Bergamo, Caserta, Florence, Genoa, Milan, Napoli, Ravenna, Rome, Verona
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Aviano, Milan, Naples, Orbassano, Parma, Ravenna, Rome
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 1/2Taking people
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Where
Milan, Orbassano, Padova, Parma, Ravenna, Rome
Age
18 years and over
People
160 worldwide
Run by
TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00
No phaseTaking people
Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer
Where
Pavia
Age
18 years and over
People
180
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT05384873
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Bari, Bologna, Catania, Milan, Naples, Padova, Rome, Varese, Verona
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Milan
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Avellino, Aviano, Bologna, Florence, Lecce, Meldola, Milan, Orbassano, Padova, Palermo, Rome, Rozzano, Verona
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Bari, Catania, Genova, Meldola, Milan, Monza, Naples, Orbassano, Rome, Verona
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Bergamo, Milan, Naples, Perugia, Siena
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
No phaseNot yet taking people in Italy
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
Where
Milan
Age
18 years and over
People
360
Run by
European Institute of Oncology
See details and how to joinNCT07815873
Phase 3Taking people
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Where
Aviano, Catania, Firenze, Medolo, Ravena, Reggio Emilia, Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi, Azienda USL Toscana Sud Est -Ospedale Misericordia - Grosseto, Azienda Ospedaliero-Universitaria di Modena (AOU Modena) - Policlinico di Modena, Azienda Ospedaliera San Gerardo - Monza, Azienda Ospedaliero - Universitaria di Parma, IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena, Azienda Ospedaliera Universitaria Senese - (ITT) - Center for Immuno-Oncology (CIO), La Maddalena Casa di Cura di Alta Specialita - Palermo
Age
18 years and over
People
65 worldwide
Run by
Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00